I will now assess the research paper "Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study" based on the Top 10 Dimensions of Research Impact. Here’s the detailed analysis:

1. Domains of Research Impact (RI)
Excerpts: The study significantly impacts the health domain, focusing on the treatment of psoriatic arthritis (PsA). The findings demonstrate rapid and sustained improvements in pain relief using secukinumab, impacting both clinical practice and patient quality of life.
Section: Results, Discussion - Pages 2-3​(6).
Example: The introduction of secukinumab as an effective treatment for PsA may influence clinical guidelines and treatment protocols for managing chronic inflammatory diseases, improving patient outcomes across healthcare settings.
2. Duration of Research Impact (RI)
Excerpts: The impact of secukinumab is both short-term and long-term, with rapid pain relief reported by week 3 and sustained benefits observed up to 2 years.
Section: Results - Page 3​(6).
Example: In the short-term, healthcare providers could adopt secukinumab as a new option for immediate relief in PsA patients. Long-term, the sustained efficacy of the drug could influence future PsA management and ongoing research into IL-17A inhibitors.
3. Stakeholder of Research Impact (RI)
Excerpts: The primary stakeholders are patients with PsA, healthcare providers, and researchers in rheumatology. The study addresses the needs of patients who experience severe pain and discomfort, with clinicians benefiting from a new therapeutic tool.
Section: Methods and Results - Pages 1-3​(6).
Example: Patients directly benefit from improved pain management. Healthcare professionals gain an evidence-based treatment alternative for PsA, and researchers can build upon the findings to explore IL-17A inhibitors' broader applications.
4. Depth and Breadth of Impact
Excerpts: The study has a deep impact within rheumatology and immunology, advancing knowledge of PsA treatment with biologics targeting IL-17A. Its broad impact may extend to other autoimmune diseases where IL-17A plays a role.
Section: Discussion - Page 6​(6).
Example: The research deepens understanding of PsA treatment mechanisms and could lead to broader applications in treating similar autoimmune conditions such as ankylosing spondylitis or rheumatoid arthritis.
5. Scalability and Transferability
Excerpts: The findings are scalable across different PsA populations and transferable to similar inflammatory conditions that respond to IL-17A inhibition.
Section: Methods - Page 3​(6).
Example: The success of secukinumab in PsA treatment could be scaled to larger, global healthcare systems for treating a broader PsA population and transferred to other autoimmune diseases like psoriasis or rheumatoid arthritis.
6. Innovation and Disruption Potential
Excerpts: Secukinumab represents an innovative treatment in targeting IL-17A, offering a new approach in managing PsA. This treatment could disrupt traditional TNF inhibitor treatments by providing an alternative for patients unresponsive to TNFis.
Section: Discussion - Page 7​(6).
Example: Secukinumab may disrupt the current PsA treatment paradigm by establishing IL-17A inhibition as a primary therapeutic option, potentially shifting clinical practice away from TNF inhibitors.
7. Sustainability and Ethical Considerations
Excerpts: The treatment offers sustainable long-term pain relief for PsA, and the study follows ethical standards in clinical trials, ensuring patient safety and informed consent.
Section: Methods - Page 2​(6).
Example: The use of secukinumab could lead to sustained improvements in quality of life for PsA patients, reducing the need for long-term corticosteroid use and other medications that may have more severe side effects.
8. Implementation and Usability
Excerpts: Secukinumab’s subcutaneous administration is user-friendly for both healthcare providers and patients, allowing ease of use in clinical practice.
Section: Methods - Page 2​(6).
Example: The simplicity of subcutaneous administration makes secukinumab highly implementable in routine clinical settings, ensuring broad usability among PsA patients.
9. Cross-disciplinary and Global Relevance
Excerpts: The study has global relevance as PsA affects populations worldwide, and secukinumab could be applied universally. It also has cross-disciplinary applications, potentially influencing dermatology, rheumatology, and immunology.
Section: Background - Page 1​(6).
Example: The findings are relevant to global health, with secukinumab potentially becoming a standard treatment in international PsA management guidelines. Its effectiveness could influence other disciplines, such as immunology and dermatology.
10. Resilience and Adaptability
Excerpts: Secukinumab demonstrates resilience by providing sustained pain relief across diverse patient populations, including those who had inadequate responses to other treatments.
Section: Results - Page 6​(6).
Example: The treatment shows adaptability in its effectiveness among both TNF-naïve and TNF-inhibitor refractory patients, suggesting it can be tailored to a variety of patient needs within the PsA population.
This detailed analysis demonstrates the broad and deep impact of the research across several key dimensions of research impact, especially in the health domain.